首页> 外国专利> Derivatives of isoxazolina C6 and C9 - replaced; their use for the manufacture of a Medicament, and Pharmaceutical composition

Derivatives of isoxazolina C6 and C9 - replaced; their use for the manufacture of a Medicament, and Pharmaceutical composition

机译:取代的异恶唑啉C6和C9衍生物;它们用于制造药物和药物组合物的用途

摘要

1. This list refers to the substituted tricyclic isoxazolina derivatives, especially dihydrobenpiranisoxazolina and dihydro quinoolinosoxazolina derivatives, In the formula (1), there is at least one phenyl part of the tricyclic ring part at the positions of C6 and C9, and there is one radical three ring part of the selected positions, namely, dikhoronaftalenosoxazolina and dihydrobenzotioponios xazolina. 1. Preparation of drugs by using the compound; including drug synthesis of the compound, and use as drugs, especially for the treatment of depression, anxiety, motor disorders, psychosis,Parkinson's disease and weight disorders. At present, the compounds show surprisingly that they have the activity of inhibiting the reabsorption of serotonin (5-HT) in combination with the additional antagonistic activity of ALF receptor.A2 adrenaline, which shows strong antidepressant activity rather than sedatives. It is also mentioned in the present paper that isoxazolina derivatives are recombined with one or more other compounds selected from antidepressants.Antianxiety, antipsychotics and anti Parkinson's drugs to improve effectiveness and / or the beginning of action.1. A.1. Acid additive salt or pharmaceutically acceptable acid group selected from hydrogen, tar, AR, tar, tar and tar group, its stereoisomerization isomer form and positive oxidation form: X is CH2, n-r7, s or O; Ammonium carbamate and monkey and di - (TAR) carbamate; R1, R2, R14, R15 are independently selected from the hydrogen group; halogenation; a radical substance selected from the hydrogen group, so2h, so2ch3, asphalt, hydroxyoxyformic acid, carbamate, tetrahydrofuran group, Carbohydrate Xipyridinylcarbonyloxy, alkylcarbonyloxyalkyloxy, alkyloxyalkylcarbonyloxyalkyloxy, alkyloxycarbonyloxy, alkenyloxy, alkenylcarbonyloxy, mono- or di (alkyl) aminoalkyloxy, mono- or di (alkyl) aminocarbonyloxyalkyloxy; a radical selected from the group of cyano, CN-OH, CN-oxyalkyl, alkyl, alkyloxyalkyl, alkyloxyalkyloxyalkyl, alquiloxialquiloxialquiloxialquilo, alkylcarbonylalkyl, alkylcarbonyloxyalkyl, alkyloxycarbonylalkyl, Ar-alkyl, Ar-carbonylalkyl, Ar-oxyalkyl, mono- or di (alkyl) aminoalkyl , mono- or di (alkylcarbonyl) aminoalkyl, mono- or di (alkyl) aminocarbonyl-,alkyl, Het-alkyl, formyl, alkylcarbonyl, alkylcarbonyl, alkyloxyalkylcarbonyl, mono- or di (alkyl) aminocarbonyl, Ar-carbonyl and Ar-oxycarbonyl; -N-R10R11 where R10 and R11 each, independently of the other, are selected from the group consisting of hydrogen, alkyl, Ar, pyridinyl, Ar-alkyl, pyrrolidinyl alkyl, piperidinyl alkyl, homopiperidinyl alkyl, piperazinyl alkyl, morpholinyl alkyl, mono- or di (alkyl ) aminocarbonyl, alkylcarbonyl, alkenylcarbonyl, Ar-carbonyl, pyridinylcarbonyl, alkyloxycarbonyl, mono- or di (alkyl) aminocarbonyl, mono-di (Ar) aminocarbonyl, mono- or di (alkyloxycarbonylalkyl) aminocarbonyl, pyrrolidinylcarbonyl,1. Carbamate, polyaminobenzamide, n-phenylpyridyl methyl ester, alkylhydrazide, and AR sulfonilo;Or R10 and R11 can be used together to form a monovalent radical selected from the formula residue group (2),Among them, R12 is selected from hydrogen, asphalt, AR, AR asphalt, AR alquenilo, asphalt, tar, tar, carbamate or di - (TAR) aminobenzene; each R13 is,Independent of one of another group of substances composed of asphalt, oxo, AR, AR asphalt, AR acquilo, AR alquenilo and hydrocarbon poisoning; q is an integer of 0-6; aspha AR and het; provided that at least one R14 and R15 are not hydrogen. AR is phenyl or nafilo, which can be replaced by one or more halogens, cyanogens, oxo, hydroxy, hydrocarbyl, hydrocarbyl, thyroid, hydrocarbyl or amino groups; het is a heterocyclic radical substance selected from het1, het2 and het3 groups; hett1 is a heterocyclic monocyclic aromatic radical substance selected from pirrolidini, dioxylo and imidazolidini groups, Pyridienediene, morphine dienediene, dienedieneHet2 is a semi aromatic, single cycle and anti cyclical radical substance of 2H pirrolilo, pyridinol, pyridine xylene and pyridine diene; hett3 is a single cycle and anti cycle and anti cycle radical substance selected from pyridinol, pyridine diene, pyridine diene, pyridine diene, furan, geranyl ester and oxazolilo, 1. Thiazolyl, isothiazolyl, pyridylene, pyridylene, pyridylene, pyridylene, and trizinc; or two cycloaromatics selected from quinoolinil, quinoxalilo, indolilo, benimidazolo, benzoxazollo, benisoxazollo, benzotiazolo, benzofuranilo and benzotianilo;In this case, each het radical may be replaced by carbon or heteroatom, halogenated, hydrogen Xi, asphalt, tar, tar, AR, asphalt, thyroid, tar or pyridine; a and B are asymmetric centers; (CH2) (m) is a straight Carbide chain composed of protons m, M is an integer 1 to 4 carbon atom; PIR is a radical agreement to replace any one of the alternative groups with n-radical R8, where each R8 is,Independently selected from the groups of hydrogen Xi, amino group, nitro group, cyanogen group, halogen group and tar group; n is the integer 0 to 5; R9 is selected from the groups of hydrogen, tar group and thyroid group; R3 represents a selective aromatic ring system with the same or different ring, and is replaced with some carbide chains. O complete hydrogenation can selectively replace 1 to 6 atoms in length to combine the ring system with the giant reactor, and may contain one or more heteroatoms selected from the O, N and s groups;1. Tar refers to a saturated straight-line or separator like hydrocarbon base composed of C1-6 or circulating C3-6 saturated hydrogen carbide filter, which can be optionally replaced by one or more halogenated, oxo, hydroxi, thyroid or amino bodies, and represents an unsaturated straight-line or separator like carbide filter. One or more radicals in the group of halogenated, cyanogen, oxo, hydroxy, thyroid or aminobenzene can be selected to replace the double bond.
机译:1.该列表是指取代的三环异恶唑啉衍生物,特别是二氢苯并吡喃异恶唑啉和二氢喹啉并恶恶唑啉衍生物,在式(1)中,三环部分的至少一个苯基部分在C6和C9的位置,并且一个所选位置的三环基团的自由基,即二khoronaftalenosoxazolina和dihydrobenzotioponios xazolina。 1.用该化合物制备药物;包括该化合物的药物合成,以及用作药物,特别是用于治疗抑郁症,焦虑症,运动障碍,精神病,帕金森氏病和体重障碍。目前,这些化合物令人惊讶地显示出,它们具有抑制5-羟色胺(5-HT)重吸收的活性,并具有ALF受体A2肾上腺素的附加拮抗活性,该化合物具有较强的抗抑郁活性而不是镇静剂。本文还提到将异恶唑啉衍生物与一种或多种选自抗抑郁药的其他化合物重新组合,以提高抗焦虑,抗精神病药和抗帕金森氏症药物的作用和/或作用开始。1。 A.1。选自氢,焦油,AR,焦油,焦油和焦油基团的酸加成盐或药学上可接受的酸基,其立体异构化异构体形式和正氧化形式:X为CH 2,n-r 7,s或O;氨基甲酸铵和猴子以及氨基甲酸二-(TAR); R1,R2,R14,R15独立地选自氢基;卤化;选自氢,SO 2 H,SO 2 CH 3,沥青,羟氧基甲酸,氨基甲酸酯,四氢呋喃基团,碳水化合物水吡啶基羰基氧基,烷基羰基氧基烷基氧基,烷基氧基烷基羰基氧基烷基氧基,烷基氧基羰基氧基,烯基氧基,烯基羰基氧基,单或二(烷基)氨基烷基氧基,一或二(烷基)氨基羰基氧基烷氧基;选自氰基,CN-OH,CN-氧基烷基,烷基,烷氧基烷基,烷氧基烷基氧基烷基,alquiloxialquiloxialquiloxialquilo,烷基羰基烷基,烷基羰基氧基烷基,烷氧基羰基烷基,Ar-烷基,Ar-羰基烷基,Ar-氧基烷基,一或二(烷基)基团的基团氨基烷基,单或二(烷基羰基)氨基烷基,单或二(烷基)氨基羰基,烷基,杂烷基,甲酰基,烷基羰基,烷基羰基,烷氧基烷基羰基,单或二(烷基)氨基羰基,Ar-羰基和Ar-氧羰基; -N-R10R11,其中R10和R11彼此独立地选自氢,烷基,Ar,吡啶基,Ar-烷基,吡咯烷基烷基,哌啶基烷基,高哌啶基烷基,哌嗪基烷基,吗啉基烷基,单-或二(烷基)氨基羰基,烷基羰基,烯基羰基,Ar-羰基,吡啶基羰基,烷氧基羰基,单-或二(烷基)氨基羰基,单-二(Ar)氨基羰基,单-或二(烷氧基羰基烷基)氨基羰基,吡咯烷基羰基,1。氨基甲酸酯,聚氨基苯甲酰胺,正苯基吡啶基甲基酯,酰肼和AR磺酰基;或R10和R11一起形成选自式残基(2)的一价基团,其中R12选自氢,沥青, AR,AR沥青,AR Alquenilo,沥青,焦油,焦油,氨基甲酸酯或二-(TAR)氨基苯;每个R 13独立于由沥青,氧代,AR,AR沥青,AR acquilo,AR alquenilo和碳氢化合物中毒组成的另一组物质中的一个; q是0-6的整数;沥青; AR和het;前提是至少一个R14和R15不是氢。 AR是苯基或萘菲基,其可以被一个或多个卤素,氰基,氧代,羟基,烃基,烃基,甲状腺,烃基或氨基取代; het是选自het1,het2和het3组的杂环自由基物质; hett1是选自吡咯烷基,二氧基和咪唑烷基的杂环单环芳香族自由基物质,吡啶二烯,吗啡二烯,二烯二烯Het2是2H吡咯烷酮,吡啶醇,吡啶二甲苯和吡啶二烯的半芳族单环和反环自由基物质; hett3是单循环和反循环及反循环自由基物质,选自吡啶醇,吡啶二烯,吡啶二烯,吡啶二烯,呋喃,香叶基酯和恶唑利洛。1.噻唑基,异噻唑基,吡啶基,吡啶基,吡啶基,吡啶基和三嗪;或两个选自环喹啉,喹喔啉,吲哚洛,苯并咪唑,苯并恶唑,苯并恶唑,苯并噻唑,苯并呋喃基和苯并噻吩基的环芳族化合物;在这种情况下,每个het自由基可被碳或杂原子,卤代,氢Xi,沥青,焦油,焦油,AR ,沥青,甲状​​腺,焦油或吡啶; a和B是不对称中心; (CH2)(m)是由质子m组成的直链碳化物链,M是1-4个整数的碳原子; PIR是一个基本协议,可以用n自由基R8取代任何一个替代基团,其中每个R8独立地选自氢Xi,氨基,硝基,氰基,卤素基团和焦油基团; n是0至5的整数; R9选自氢,焦油基和甲状腺基; R 3代表具有相同或不同环的选择性芳族环系统,并被某些碳化物链取代。完全氢化可选择性取代1至6个长度长的原子,以使环系统与巨型反应器结合,并可能包含一个或多个选自O,N和s组的杂原子; 1。焦油是指由C1-6或循环的C3-6饱和碳酸氢盐过滤器组成的饱和直线或分离器,如碳氢化合物碱,可以可选地被一个或多个卤代,氧代,羟基,甲状腺或氨基取代不饱和直线或类似碳化物过滤器的分隔符。可以选择卤代,氰基,氧代,羟基,甲状腺或氨基苯中的一个或多个基团来取代双键。

著录项

  • 公开/公告号AR041020A1

    专利类型

  • 公开/公告日2005-04-27

    原文格式PDF

  • 申请/专利权人 JANSSEN PHARMACEUTICA N.V.;

    申请/专利号AR2003P103002

  • 发明设计人

    申请日2003-08-20

  • 分类号C07D498/04;A61K31/424;A61P25/00;

  • 国家 AR

  • 入库时间 2022-08-21 22:18:51

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号